InflaRx N.V. (IFRX) vs Lexeo Therapeutics, Inc. (LXEO)

InflaRx N.V. and Lexeo Therapeutics, Inc. are both Biotechnology companies. InflaRx N.V. and Lexeo Therapeutics, Inc. are of similar size ($284.4M and $278.3M). Across the 11 metrics below, InflaRx N.V. leads on 7 and Lexeo Therapeutics, Inc. on 4.

Valuation

Metric IFRX LXEO Biotechnology median
P/E n/m n/m 7.88
P/S 7,267.48 n/m 11.47
P/B 1.31 1.21 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1,130.56 n/m 10.73
Earnings yield (30.69%) (34.74%) (28.84%)
Free cash flow yield (12.29%) (31.30%) (23.03%)

Profitability

Metric IFRX LXEO Biotechnology median
Gross margin (26,762.42%) 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (38.71%) (46.76%) (57.72%)
Return on assets (32.75%) (40.50%) (49.22%)
Return on invested capital 0.00% (253.48%) 0.00%

Growth

Metric IFRX LXEO Biotechnology median
Revenue growth (TTM) (83.39%) — 5.64%
EPS growth (last fiscal year) 9.41% 39.81% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IFRX LXEO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.22 13.89 4.73
Net debt to EBITDA 0.97 1.67 0.96

Dividend

Metric IFRX LXEO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric IFRX LXEO Biotechnology median
Market cap 284.42m 278.28m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack